Intracrystalline Ozurdex® implant: iatrogenic intravitreal injection management

The intravitreal dexamethasone implant Ozurdex® (Allergan, Inc, Irvine, Calif.) is indicated for the treatment of diabetic macular edema, venous occlusion of the retinal vessels, and noninfectious uveitis. In phakic patients, it is suggested that the injection should be done 4 mm posterior to the corneal limbus, directing the needle to the optic nerve, preferably in the inferotemporal quadrant. Although it is a rare event, inadvertent...